A potential prognostic lncRNA signature for predicting survival in patients with bladder urothelial carcinoma

Increasing evidence has highlighted the critical roles of long non-coding RNA (lncRNA) in cancer development and progression. However, the prognostic power of expression-based lncRNA signature for predicting overall survival in patients with Bladder Urothelial Carcinoma (BLCA) has not been investigated. Here, we performed a comprehensive analysis for lncRNA expression profiles and corresponding clinical information of 234 BLCA patients from The Cancer Genome Atlas (TCGA). We established a set of four-lncRNAs that were significantly associated with BLCA patients' survival. Using the prognostic four-lncRNA signature, we successfully classified the BLCA patients into high-risk and low-risk groups, and the prognostic power of the four-lncRNA signature was further validated in the testing dataset and entire dataset. Multivariate Cox regression and stratified analyses demonstrated that the prognostic power of the four-lncRNA signature was independent of other clinical variables. Functional enrichment analyses suggested the four prognostic lncRNAs may be involved in known BLCA-related biological processes and pathways. Our results demonstrated that the four-lncRNA signature could be novel independent biomarkers for predicting survival in patients with BLCA.

Oncotarget. 2017 Jan 02 [Epub ahead of print]

Zhenyu Bao, Weitao Zhang, Dong Dong

Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences, School of Life Sciences, East China Normal University, Shanghai, China., Urology Surgery Department, Affiliated Hospital of Taishan Medical University, Shandong, China.